Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder (PharmICO)

This project will provide novel empirical information about how to optimally engage pharmacists and pharmacies as key partners in collaborative integrated care models designed to expand access to evidence-based medication treatment for OUD which may inform a larger experimental design that seeks to evaluate best ways to scale-up this model across the nation. This Phase 1 project seeks to evaluate the feasibility, acceptability, and impact of implementing a pharmacist-integrated model of MOUD into approximately four diverse outpatient clinical sites.

Study Overview

• Status: Completed
• Conditions: Opioid Use Disorder; Substance Use Disorders
• Intervention / Treatment: Other: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)

Detailed Description

Pharmacists remain an underutilized resource in the treatment of opioid use disorder (OUD). Although studies have engaged pharmacists in dispensing medications for OUD (MOUD), few studies have evaluated collaborative care models in which pharmacists are an active, integral part of a primary care team offering OUD care. In this Phase 1 project, the investigative team seeks to implement a Pharmacist-Integrated Medication Treatment for OUD (PrIMO) clinical model and will evaluate its feasibility and acceptability as well as its impact on clinical sites' capacity for MOUD care and on patient outcomes in OUD care.

This project will provide novel empirical information about how to optimally engage pharmacists and pharmacies as key partners in collaborative integrated care models designed to expand access to evidence-based medication treatment for OUD which may inform a larger experimental design that seeks to evaluate best ways to scale-up this model across the nation.

The PrIMO model is standard of care at a federally qualified health center in Maine and is based on the primary care pharmacist role utilized at health clinics around the US and internationally. This study will explore the implementation of this model at diverse clinics.

This Phase 1 project seeks to leverage the PrIMO model to:

Aim 1: Employ a mixed-methods approach to evaluate the feasibility of implementing a pharmacist-integrated model of MOUD into approximately four diverse outpatient clinical sites.

Aim 2: Evaluate the acceptability and impact of implementing the pharmacist-integrated model.

Primary Outcome Measure: The Stages of Implementation Completion (SIC) is a measure of implementation process and milestones. The SIC is the overarching measure used to assess progress towards successful implementation (i.e., extent to which each collaborating clinical site implements and sustains the numerous key activities within the PrIMO model).

Secondary Outcome Measures: The study's secondary outcomes are to explore the acceptability and impact of the PrIMO model. To assess acceptability, the study will utilize the Applied Mental Health Research Dissemination and Implementation (AMHR) tool, Clinical Sustainability Assessment Tool (CSAT), Medical Conditions Regard Scale, Substance Use Stigma Mechanism Scale, Beliefs on MOUD Survey, Implementation Citizenship Behavior Scale, PrIMO Fidelity Checklist, Cost of Implementing New Strategies (COINS) tool, and qualitative interviews. To assess impact, the study will explore treatment outcomes and capacity for MOUD via electronic health record (EHR) data extraction at each site.

The study will engage approximately four clinical outpatient sites. At each site, the study team will enroll participants in two subgroups: (1) site staff (including providers [may include MD, DO, PA, NP, nurse, behavioral health clinician, and/or social worker pending site variation], pharmacists, pharmacy technicians, administrators [may include CEO, CFO, CMO, medical assistants, front desk staff, clinic and/or team manager pending site variation]) and (2) patients.

Site Staff (range per site) Providers n=5-20 Pharmacists n=2-6 Pharmacy Technicians n=2-10 Administrators n=2-10

Patients (per site) n=12-40

Consented and enrolled participants will be 18 years or older, not considered prisoners at enrollment, and either employed by (site staff) or receiving MOUD (patients) from the site clinic implementing the PrIMO model.

Feasibility (Phase 1) Approximately four sites in the United States representing diverse patient populations (e.g., gender, race, ethnicity, geography) and at least one clinic-based pharmacist, at least one X-waivered primary care provider already providing MOUD treatment and a retail pharmacy (optimally employed by the clinic organization and/or co-located with the clinic) will be selected. The pharmacy and clinic staff must have shared access to each other's EHR systems, and sites must agree to provide clinic and pharmacy EHR data to the study team.

As the PrIMO model is considered standard of care in the originating clinic and is based on the national recognition of the role pharmacists play in collaboration with primary care, this is not a study evaluating an experimental intervention. And there is no experimental manipulation in this study. It is a study of the feasibility of implementing the PrIMO model of care in a diverse array of clinical sites.

As this is a minimal risk study examining the implementation of a standard of care clinical model, there will be no safety monitoring, and safety reporting will be limited to patient participant deaths.

Statistical methods will be largely descriptive, as this study is not testing a formal hypothesis. As a longitudinal mixed methods implementation feasibility study, analyses will include quantitative and qualitative analyses at the site, site staff, and patient levels. Analyses at the site level will be purely descriptive in nature and precision estimates for key secondary outcomes at the staff, provider and patient level will be conducted.

Data collection will begin approximately 3 months prior to sites launching the PrIMO model and will continue through 12-months post-launch. Patient participants will be enrolled beginning at implementation launch (after at least a 2-week exposure period to the PrIMO model) and will be asked to participate for 6 months' time, allowing for approximately 6 months of patient enrollment at each site (depending on actual date of launch). These timelines should ensure 15 months for collection of study outcome measures.

EHR data will be collected from each site for up to 12 months pre-launch and 12 months post-launch.

Site Staff participants will engage at approximately 3 months pre-launch, launch, and 3, 6, 9, and 12-months post-launch, totaling 15 months of study participation for those engaged throughout the full period.

Recruitment of patient participants will begin at launch. Patients will be enrolled after at least 2 weeks' exposure to the PrIMO model (whether new or existing prior to launch) and will follow-up at 3- and 6-months post-baseline, totaling up to 6 months of study participation.

• Study Type: Interventional
• Enrollment (Actual): 149
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New Hampshire
    • Nashua, New Hampshire, United States, 03062
      • Harbor Health Care
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • UNM Truman Health Services
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Sugar House Health Center
  • Washington
    • Tacoma, Washington, United States, 98404
      • Community Health Care

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Study Population

As this is a feasibility study, participants will be comprised of key groups of site staff (providers, pharmacists, pharmacy technicians, and administrators) and patients at the clinic who have been exposed to the PrIMO model. This study will only obtain data from a sample of participants from each site.

Description

Inclusion Criteria:

Site Staff

• 18 years of age and older.
• Employed at the clinic as an identified stakeholder role (provider, pharmacist, pharmacy technician, or administrator).

Patients

• 18 years of age or older.
• A patient of the participating clinic who is receiving or has received MOUD from a provider employed by the clinic.
• Exposed to the PrIMO model at the clinic site for at least 14 days.

Exclusion Criteria:

Site Staff

• Unwilling or unable to provide consent
• Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities.

Patients

• Not able to speak English sufficiently to understand study procedures and provide written informed consent.
• Unable or unwilling to provide consent or to participate in study procedures.
• Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Site Staff; Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments	Other: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO); This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
Other: Patients; Subset of patients receiving PrIMO care to receive survey assessments	Other: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO); This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stages of Implementation Completion (SIC) Tool	The SIC is a date-driven measure of implementation milestones spanning activities from the Pre-implementation through Competency stages of implementation.	Up to 100 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Applied Mental Health Research Dissemination & Implementation (AMHR) Tool	The AMHR will be used to assess acceptability of implementing the PrIMO model. The AMHR is a tool that assesses stakeholder perceptions of implementation across a variety of settings. The AMHR has three separate scales for use with specific populations: leadership, providers, and consumers. The items within these scales are all rated on a Likert system of Strongly disagree (0) to Strongly Agree (3). Generally, an increase in scale rating indicates higher levels of acceptability.	3 months pre-model launch through 12 months post-model launch
Clinical Sustainability Assessment Tool for PrIMO	The Clinical Sustainability Assessment Tool (CSAT) is a 35-item tool spread across seven sustainability domains, with five items per domain. For this study, the CSAT has been modified to incorporate PrIMO and renamed the "Sustainability Assessment Tool for PrIMO". The CSAT uses a Likert system of "To little or no extent" (1) to "To a very great extent" (7). Generally, an increase in scale rating indicates higher levels of sustainability.	3 months pre-model launch through 12 months post-model launch
Medical Conditions Regard Scale	The Medical Conditions Regard Scale (MCRS) is a non-condition-specific scale to capture biases, emotions, and expectations generated by medical condition descriptors. The MCRS uses a Likert system of "Strongly Disagree" (1) to "Strongly Agree" (6). Generally, an increase in scale rating indicates negative perspectives of patients with specified medical conditions.	3 months pre-model launch through 12 months post-model launch
Substance Use Stigma Mechanism Scale	The full SU-SMS contains subscales related to Enacted (how people have treated you in the past), Anticipated (how likely is it that people will treat you this way in the future), and Internalized (how do you feel now). For the purposes of this study, only the Internalized subscale will be utilized. The SU-SMS uses a Likert system of "Strongly Disagree" (1) to "Strongly Agree" (5). Generally, an increase in scale rating indicates negative feelings of internal stigma.	3 months pre-model launch through 12 months post-model launch
Beliefs on MOUD Modified	The survey will be used to understand prescriber perceptions of and barriers to utilizing medication treatment for opioid use disorder.	3 months pre-model launch through 12 months post-model launch
Implementation Citizenship Behavior Scale	The Implementation Citizenship Behavior Scale measures the behaviors that exceed expected tasks performed by employees at the site to support the implementation of the PrIMO model. The ICBS uses a Likert system of "Not at All" (0) to "Frequently if not always" (4). Generally, an increase in scale rating indicates positive implementation citizenship.	3 months pre-model launch through 12 months post-model launch
Qualitative interviews	Interviews with a subset of participants will provide additional context and salient themes of implementing the model that may not be captured through the quantitative measures.	3 months pre-model launch through 12 months post-model launch
Electronic health record data	Limited data will be collected from EHR records according to a study-specific Data Dictionary.	Model launch through up to 18 months post-launch

Collaborators and Investigators

• Sponsor: Trustees of Dartmouth College
• Collaborators: National Institute on Drug Abuse (NIDA)
• Investigators: Principal Investigator: Lisa A Marsch, PhD, Geisel School of Medicine at Dartmouth College

Study record dates

Study Major Dates

• Study Start (Actual): August 18, 2022
• Primary Completion (Actual): August 31, 2024
• Study Completion (Actual): February 5, 2025

Study Registration Dates

• First Submitted: March 14, 2022
• First Submitted That Met QC Criteria: March 25, 2022
• First Posted (Actual): April 5, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 23, 2025
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Narcotic-Related Disorders; Mental Disorders; Chemically-Induced Disorders; Opioid-Related Disorders; Substance-Related Disorders; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Narcotics; Analgesics, Opioid
• Other Study ID Numbers: CTN-0116

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No